LifeVantage announces new in vitro study results for P84 formula

LifeVantage (LFVN) Corporation announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration. In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP and SST were thoroughly examined. All 14 peptides were influenced in the desired direction, with key results including: GRP: +1,087% increase; TFF3: +116% increase; VIP: +100% increase; OXM: +77% increase; CCK: +69% increase.